About this trial
The ACTIONcardioRisk trial is designed to investigate the effect of aerobic and progressive resistance training exercises combined with cognitive training, on neurocognitive functioning of sedentary older adults with and without cardiovascular risk factors.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Adult aged 60 and older,
Normal or corrected vision and normal hearing for their age range,
No cognitive impairment (Mini-Mental State Examination - MMSE ≥ 25),
Inactive (< 150 min of physical activity per week).
Disqualifiers
MMSE ≤ 24 or diagnosis of dementia,
Uncontrolled psychological / psychiatric condition within the past 6 months,
Neurological disease,
Severe exercise intolerance,
Trial design
Parallel
Treatments tested in this trial
Cognitive Training
Other interventionParticipants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer- or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general.
Aerobic and resistance exercises
Other interventionParticipants will follow a periodized exercise training program with thrice-weekly 60 minutes trainings. The sessions will start with a 5-10mins warm-up, followed by aerobic and resistance trainings, and ends with a 5-10mins cool-down and stretching period. Intensity of aerobic sessions will be monitored with heart rate chest strap and should match with the moderate to vigorous intensity zone as defined by the ACSM (65% of Heart Rate maximum or more and a Perceived Exertion higher than 12 on the 6 to 20 Borg scale). Exercise intensity and duration will be gradually increased during the program. After aerobic training, a 15-20mins resistance training will be performed with a gradual progression of higher intensities and/or numbers of sets. The one maximal repetition (1RM) will be assessed for each RT movements at baseline, during (each 3 months) and at the end of the program. RT intensities will go from 40 to 70% of 1RM, with 8 to 10 forms of exercise involving majors muscle groups.
Stretching and Toning
Other interventionParticipants in the active control condition will take part in three 60 minutes stretching and toning sessions per week. Each session will start with a five-minutes warm-up, followed by fifteen min of body stretching exercises mainly in a seated position and finish with a five-minutes cool down. Participants will engage in four muscle-toning exercises (light intensity) using dumbbells or resistance bands, two exercises designed to improve balance, one yoga sequence, and one exercise of their choice. Intensity of stretching and toning sessions will be monitored with heart rate chest strap and should not exceed the light intensity zone as defined by the ACSM (64% of Heart Rate maximum or less and a Perceived Exertion lower than 11 on the 6 to 20 Borg scale).
Treatment groups
Trial outcomes
Primary outcomes
Change in general cognitive functioning
Montreal Cognitive Assessment (0-30 score, with a higher score indicating a better cognitive functioning).
Change in processing speed
Validated remote version of neuropsychological tests and iPad tests (Composite Z-score).
Change in executive functions
Validated remote version of neuropsychological tests and iPad tests (Composite Z-score).
Change in episodic memory
Validated remote version of neuropsychological tests and iPad tests (Composite Z-score).
Secondary outcomes
Change in cerebral autoregulation - frontal cortical region
Variations of prefrontal cortical oxygen saturation (rSO2, \[HbO\]/(\[HbO\]+\[HbR\])) will be measured by Near Infrared Spectroscopy (NIRS), as a surrogate of cortical blood flow. Variations of continuous peripheral blood pressure (mm Hg) will be simultaneously measured by plethysmography at the finger. Autoregulation indices (unitless) will be derived from the correlation between variations of oxygen saturation measures and variations of peripheral blood pressure.
Change in cerebral autoregulation - middle cerebral arteries
Variations of cerebral blood flow velocity (cm/s) at the level of the middle cerebral artery will be measured by Transcranial Doppler (TCD). Variations of continuous peripheral blood pressure (mm Hg) will be simultaneously measured by plethysmography at the finger. Autoregulation indices (unitless) will be derived from the correlation between variations of cerebral blood flow measures and variations of peripheral blood pressure.
Change in cerebral vasoreactivity - whole brain
Cerebral VasoReactivity (CVR, % change per mm Hg of PaCO2) will be measured by Arterial Spin Labeling MRI in two third of the study participants who do not present contra-indication for imaging studies.
Change in cerebral vasoreactivity - prefrontal cortex
Cerebral VasoReactivity (CVR, % change per mm Hg of PaCO2) will be measured using NIRS in the prefrontal region.
Other outcomes
Change in cardiorespiratory fitness
Maximum incremental cardiopulmonary exercise test (VO2 max (ml.kg.min)).
Change in peripheral endothelial function
Fow-mediated dilation of the brachial artery (%).
Change in central artery stiffness
Carotid femoral pulse-wave velocity (m/s).
Change in walking speed
Timed 10-meter walking test (cm/s).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Louis Bherer
Lead sponsor
Montreal Heart Institute
Sponsor institution
Canadian Institutes of Health Research (CIHR)
Collaborator
The Montreal Health Innovations Coordinating Center (MHICC)
Collaborator